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OBJECTIVE: This paper presents the results of an eco-
nomic evaluation comparing Letrozole, a third generation
aromatase inhibitor, and Tamoxifen as ﬁrst-line hormonal
therapies in postmenopausal women diagnosed with
advanced breast cancer in Germany. METHODS: A
recently published economic model was applied in which
data from a recent RCT comparing Letrozole and 
Tamoxifen were employed supplemented with data from
the literature and expert panels German cost data was
introduced. These data were synthesised within a Markov
process that described relevant events along patients path-
ways from diagnosis to death and analysed using decision
modelling software. The evaluation perspective was that
of the German healthcare system. The time horizon
covered the full lifetime of the patients. Discount rates of
5% for resources and 5% for life years were applied to
all analyses due to missing guidance in Germany like UK
Treasury guidelines. A probabilistic sensitivity analysis
was undertaken in line with the original model.
RESULTS: The mean baseline results derived from the
stochastic analysis of the model for both Letrozole and
Tamoxifen show that patients receiving Letrozole gain
additional 0.30 life years, whilst the difference in lifetime
treatment costs is €802.45. The mean cost of gaining an
additional life year from the use of Letrozole was esti-
mated as €2,673.50. Limits of the “credible interval” for
the incremental cost-effectiveness ratio (ICER) were at the
5th percentile “Letrozole dominating”, whilst the 95th
percentile reveals an ICER of €7,394.75 per life year
gained. CONCLUSION: The model extrapolated the
available clinical trial data using published data, expert
opinion and German cost data to estimate the cost per
life year saved in Germany compared to the standard ﬁrst-
line therapy of Tamoxifen. The mean results indicate that
in Germany Letrozole is a cost-effective alternative ﬁrst-
line therapy compared to Tamoxifen.
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OBJECTIVE: Most newly diagnosed non-small cell lung
cancers are too advanced at detection to be surgically
amenable. Recently it was found that poly-chemotherapy
may improve these patients’ survival signiﬁcantly, but 
no single regimen has yet been deﬁnitely determined as
preferable. This study reports an economic evaluation of
cisplatin-paclitaxel, considered the standard therapy in
the trial, compared to cisplatin-gemcitabine and pacli-
taxel-gemcitabine respectively. METHODS: Data on the
use of medical resources were collected in a phase III clin-
ical trial comparing the regimens. Costs are determined
from the viewpoint of the Dutch health insurance system.
The principal outcome measure for the economic evalu-
ation is mean survival time estimated by a restricted
means analysis with restriction time point determined by
statistical criteria. Costs are corrected for censoring using
Lin’s subinterval method, and the impact of uncertainty
is examined by applying bootstrap techniques. The analy-
sis focuses on estimation of the joint density of cost and
outcome differences, quantiﬁcation of the uncertainty
surrounding base case point estimates and derivation 
of cost-effectiveness acceptability curves. RESULTS: Base
case estimates of costs and outcomes are virtually identi-
cal for the cisplatin-paclitaxel and cisplatin-gemcitabin
groups. Average total cost (ATC) per patient in each arm
is around €17,000, but the cost composition differs 
considerably. Higher cytotoxics costs in the cisplatin-
paclitaxel group are balanced by higher costs of 
hospitalization and blood transfusions in the cisplatin-
gemcitabin group due to a higher incidence of severe
hematological toxicities and emesis. Gemcitabin-
paclitaxel leads to considerably higher ATC of €20,900
per patient and a non-signiﬁcant reduction of survival
time compared to cisplatin-paclitaxel. CONCLUSION:
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Estimates of survival and costs are identical for cisplatin-
paclitaxel and cisplatin-gemcitabin. There was a higher
incidence of severe toxicities with cisplatin-gemcitabin,
but differences in QoL are still to be determined. 
Gemcitabin-paclitaxel is a dominated option with higher
costs and non-superior survival.
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OBJECTIVES: Colon cancer is one of the most common
malignancies in developed countries. Surgery is the
primary treatment modality for this disease. However, by
the time the patient presents with recurrent symptoms,
the disease is rarely curable by surgery even when com-
bined with other therapy. The aim was to assess the 
clinical and economic outcomes of OncoVAX®. therapy
in stage II colon cancer patients. METHODS: We have
completed a prospectively randomized, controlled clinical
trial of patients with Stage II colon cancer with active 
speciﬁc immunotherapy (ASI) using autologous tumor
cell with an immunomodulating adjuvant bacillus 
Callmette-Guérin (BCG) vaccine (OncoVAX) in an adju-
vant setting. Patients were randomized to either a control
group or (OncoVAX) therapy, after surgical resection of
the primary tumor and stratiﬁcation by stage of disease.
The cost analysis consisted of the direct health care costs.
For the model, the costs and probabilities of the several
interventions, disease stages and follow-up have been 
calculated. Survival and recurrence free survival were
used from the clinical study. Utility values were derived
from the literature. RESULTS: OncoVAX signiﬁcantly
improved survival and recurrence-free survival. The
number of life years in the OncoVAX group amounted to
6.96 and in the control group 6.17. The number of recur-
rence-free life years gained is approximately 1.14 more in
the OncoVAX group. The average costs per patient in the
OncoVAX group amounted to US$20,395 and in the
control group US$4,958. The costs per life year gained
amounted to US$19,541 and the costs per QALY
amounted to US$20,489. The total discounted cost-
effectiveness ratio was US$22,660 and the discounted
cost-utility ratio amounted to US$23,675 (discount rate:
4%). CONCLUSION: This study shows that OncoVAX
is an effective treatment modality for patients with stage
II colon cancer with a cost-effectiveness ratio in the range




COST-EFFECTIVENESS OF FONDAPARINUX VS
ENOXAPARIN AS PROPHYLAXIS AGAINST
VENOUS THROMBOEMBOLISM FOLLOWING
ORTHOPAEDIC SURGERY
Posnett J, Gordois A
University of York,York, England
OBJECTIVES: Patients undergoing major orthopaedic
surgery are at risk of deep vein thrombosis, pulmonary
embolism and subsequent complications, some of which
may be fatal. For this reason post-operative prophylaxis
is recommended. Enoxaparin is the most frequently used
chemical prophylaxis in the UK. Fondaparinux is a novel
antithrombotic whose efﬁcacy has been demonstrated,
but whose cost-effectiveness has not been assessed. We
evaluated the cost-effectiveness of fondaparinux relative
to enoxaparin over a period of ﬁve years post-surgery.
METHODS: We modeled the impact of fondaparinux 
on patient outcomes and costs to the UK National 
Health Service (NHS). Outcomes are thromboembolitic
events (symptomatic deep vein thrombosis, pulmonary
embolism) and death. Data on the incidence of throm-
boembolitic events were derived from four randomised
clinical trials comparing enoxaparin with fondaparinux,
and from a review of the literature. Resource conse-
quences were estimated from a survey of UK hospitals
and discussions with a panel of clinical experts. Costs
were estimated using mean national costs to the NHS.
RESULTS: Fondaparinux dominates enoxaparin for all of
the surgery groups studied. The number of venous throm-
boembolic events (VTE) averted with fondaparinux is 15
per 1000 procedures (Total Hip Replacement), 19.5/1000
(Total Knee Replacement), 23.3/1000 (Hip Fracture
Surgery) and 19.2/1000 (All Procedures). The number of
VTE-related deaths averted is 0.8/1000 (THR), 0.8/1000
(TKR), 5.9/1000 (HFS) and 3.1/1000 (All Procedures).
Fondaparinux reduces expected cost per patient by £18
(THR), £41 (TKR), £30 (HFS) and £29 (All Procedures).
CONCLUSIONS: Compared with current practice in the
UK, fondaparinux is cost-effective. This conclusion is sen-
sitive to the relative price difference between enoxaparin
and fondaparinux, but it is robust to variations in all of
the other key parameters in the model. We estimate that
using fondaparinux could reduce NHS costs by £3.8
million annually.
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